In contrast to many available products that are based on in vitro methodology the BMProbe isolates cells in vivo. The BMProbe is inserted into the patients’ cubital vein through a catheter or indwelling line. This means that in most cases, no additional punctuation is necessary.
The geometry of the BMProbe was optimized to screen the largest possible volume of blood in the cubital vein. Therefore, the sensitivity for detecting circulating cells is far superior to exisiting in vitro methods that work with the limited volume of a blod sample.
Once the BMProbe is withdrawn, the number of isolated cells can be determined in just over an hour. This procedure is semi-automated and requires little training. Using the BMProbe, downstream molecular diagnostics are possible.
Circulating Endothelial Cells:
Endothelial cells provide the physical interface between blood and surrounding tissue. They regulate nutrient and blood component traffic. Due to mechanical or chemical reactions endothelial cells can detach and enter the blood stream. They are then referred to as Circulating Endothelial Cells (CECs). CECs are low in healthy patients (around 4 CECs/mL) and increased in patient with Acute Conorary Artery Disease or Heart Failure patients, among others. CECs are therefore considered a biomarker to monitor arterial plaque disruption as well as treatment response.
Circulating Tumor Cells:
Circulating Tumor Cells (CTCs) represent a proven diagnostic and prognostic indicator of cancer progression. They disintegrate very early from the primary tumor and travel via the blood stream to all parts of the body. Isolating and analysing CTCs enables an earlier detection of the tumor than by using common imaging technology, resulting in a higher probability of successful treatment. Additionally, distant metastases that may even be present in early-stage patients, can be detected and identified. This can help physicians selecting the optimal treatment for each patient.